Literature DB >> 1482160

Synergistic activity of clarithromycin and minocycline in an animal model of acute experimental toxoplasmosis.

F Derouin1, B Caroff, F Chau, P Prokocimer, J J Pocidalo.   

Abstract

The efficacy of clarithromycin in a murine model of acute toxoplasmosis was studied. Clarithromycin was administered alone and concurrently with minocycline, and efficacy was assessed by survival rates and sequential determination of parasite burden in blood, brains, and lungs. Limited protection resulted from administration of each drug alone, whereas a remarkable synergistic effect followed concurrent administration. Survival of mice treated with 200 mg of clarithromycin plus 20 mg of minocycline per kg of body weight daily was 95%; that of mice treated with 50 mg of clarithromycin plus 50 mg of minocycline per kg daily was 93%. The parasite burden in the blood and organ tissues of these mice was markedly reduced compared with that in mice treated with a single agent. In mice treated with 200 mg of clarithromycin plus 50 mg of minocycline per kg per day, survival was 100% during the 30-day experiment; no parasites were found in blood and tissues.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1482160      PMCID: PMC245560          DOI: 10.1128/AAC.36.12.2852

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Clarithromycin-minocycline is synergistic in a murine model of toxoplasmosis.

Authors:  F G Araujo; P Prokocimer; J S Remington
Journal:  J Infect Dis       Date:  1992-04       Impact factor: 5.226

2.  Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dogs.

Authors:  M Barza; R B Brown; C Shanks; C Gamble; L Weinstein
Journal:  Antimicrob Agents Chemother       Date:  1975-12       Impact factor: 5.191

3.  Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group.

Authors:  B Dannemann; J A McCutchan; D Israelski; D Antoniskis; C Leport; B Luft; J Nussbaum; N Clumeck; P Morlat; J Chiu
Journal:  Ann Intern Med       Date:  1992-01-01       Impact factor: 25.391

4.  Pharmacokinetic studies on minocycline in man.

Authors:  H Macdonald; R G Kelly; E S Allen; J F Noble; L A Kanegis
Journal:  Clin Pharmacol Ther       Date:  1973 Sep-Oct       Impact factor: 6.875

5.  In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice.

Authors:  C Piketty; F Derouin; B Rouveix; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

6.  Activity of minocycline against Toxoplasma gondii infection in mice.

Authors:  H R Chang; R Comte; P F Piguet; J C Pechère
Journal:  J Antimicrob Chemother       Date:  1991-05       Impact factor: 5.790

7.  Enhanced antiparasitic activity of lipophilic tetracyclines: role of uptake.

Authors:  S K Katiyar; T D Edlind
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

8.  Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis.

Authors:  F Derouin; R Almadany; F Chau; B Rouveix; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

9.  Assessment of therapy for toxoplasma encephalitis. The TE Study Group.

Authors:  H W Haverkos
Journal:  Am J Med       Date:  1987-05       Impact factor: 4.965

10.  Activity of A-56268 (TE-031), a new macrolide, against Toxoplasma gondii in mice.

Authors:  H R Chang; F C Rudareanu; J C Pechère
Journal:  J Antimicrob Chemother       Date:  1988-09       Impact factor: 5.790

View more
  3 in total

1.  Effects of 2',3'-dideoxyinosine on Toxoplasma gondii cysts in mice.

Authors:  M E Sarciron; P Lawton; C Saccharin; A F Petavy; F Peyron
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

2.  In vitro susceptibility of Pythium insidiosum to macrolides and tetracycline antibiotics.

Authors:  Erico Silva Loreto; Débora Alves Nunes Mario; Laura Bedin Denardi; Sydney Hartz Alves; Janio Morais Santurio
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

3.  In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.

Authors:  S Romand; M Pudney; F Derouin
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.